Novel Technologies To Deliver Oral Oncology Therapies
Summary: Although oral doses are preferred by cancer patients, there are a variety of development challenges from the physiochemical properties of current and new oncology drugs in development today. These often result in poor bioavailability, patient variability and food effects, leading to complex dosing regimens and a narrow therapeutic index. This 60-minute webinar from Mark J. Ratain, M.D., Associate Director for Clinical Sciences, Comprehensive Cancer Center, The University of Chicago and formulation experts at Catalent discusses how to select an optimal formulation technology to overcome these development challenges for optimal delivery, enhancing both therapeutic performance and the patient experience.